Investors sold shares of Pfizer Inc. (NYSE:PFE) on strength during trading hours on Friday. $81.60 million flowed into the stock on the tick-up and $261.36 million flowed out of the stock on the tick-down, for a money net flow of $179.76 million out of the stock. Of all companies tracked, Pfizer had the 0th highest net out-flow for the day. Pfizer traded up $0.19 for the day and closed at $35.49
PFE has been the topic of several analyst reports. Morningstar set a $38.00 target price on shares of Pfizer and gave the company a “neutral” rating in a report on Tuesday, January 30th. UBS set a $42.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Wednesday, January 31st. Nord/LB reaffirmed a “neutral” rating on shares of Pfizer in a report on Wednesday, December 27th. Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $41.00 target price on the stock in a report on Wednesday, January 24th. Finally, Sanford C. Bernstein set a $43.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Tuesday, January 30th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $39.40.
The company has a current ratio of 1.35, a quick ratio of 1.10 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $211,267.20, a price-to-earnings ratio of 13.39, a P/E/G ratio of 1.77 and a beta of 0.91.
Pfizer declared that its Board of Directors has initiated a share repurchase program on Monday, December 18th that allows the company to buyback $10.00 billion in outstanding shares. This buyback authorization allows the biopharmaceutical company to purchase shares of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s management believes its stock is undervalued.
In other news, insider Charles H. Hill sold 42,393 shares of the firm’s stock in a transaction that occurred on Tuesday, March 6th. The shares were sold at an average price of $35.76, for a total transaction of $1,515,973.68. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director W Don Cornwell sold 1,758 shares of the firm’s stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $36.79, for a total transaction of $64,676.82. Following the transaction, the director now owns 1,000 shares in the company, valued at $36,790. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 248,037 shares of company stock worth $9,064,785. Insiders own 0.06% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in PFE. Mckinley Capital Management LLC Delaware purchased a new position in Pfizer in the 2nd quarter valued at $103,000. Earnest Partners LLC purchased a new position in Pfizer in the 4th quarter valued at $105,000. First Dallas Securities Inc. purchased a new position in Pfizer in the 4th quarter valued at $118,000. Woodard & Co. Asset Management Group Inc. ADV purchased a new position in Pfizer in the 4th quarter valued at $118,000. Finally, Delpha Capital Management LLC purchased a new position in Pfizer in the 4th quarter valued at $126,000. Institutional investors and hedge funds own 71.20% of the company’s stock.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.